Skip to content
Screener

CRISPR Therapeutics CRSP Q4 2025 Annual earnings

Reported February 12, 2026 · After market close

Revenue$864.0KMiss by $3.9M
EPS-$1.37Miss by $0.22
Revenue estimate$4.7M
EPS estimate-$1.15

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$14.8M
EPS estimate-$1.06

Financials

Q4 2025

Income statement

See full
Revenue$864.0K-97.6%
Operating income-$154.8M-140%
Net income-$130.6M-250%
EPS (diluted)-$1.35-221%

Balance sheet

See full
Cash & equivalents$347.6M+16.5%
Total debt$206.7M-7.6%
Total equity$1.9B-0.5%
Total assets$2.3B+1.0%

Cash flow

See full
Operating cash flow-$92.6M-85.0%
CapEx$517.0K+104%
Free cash flow-$93.1M-85.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$5B+48.8%
Enterprise value$4.86B+47.8%
P/S1,423.8×+1,334×

Profitability

See full
Operating margin-18,933.6%-20,374pp
Net margin-16,569.8%-17,683pp
FCF margin-9,855.5%-10,276pp

Returns & leverage

See full
Return on equity-30.2%+40.3pp
Debt / equity0.1×0.0×
Current ratio13.3×-8.8×

Segments

By product

See full
Grant$864.0K+25.0%
Collaboration Revenue--100%

FAQ

When did CRISPR Therapeutics report Q4 2025 earnings?
CRISPR Therapeutics (CRSP) reported Q4 2025 earnings on February 12, 2026 after market close.
What were CRISPR Therapeutics's Q4 2025 revenue and EPS?
CRISPR Therapeutics reported revenue of $864.0K and eps of $-1.37 for Q4 2025.
Did CRISPR Therapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $4.7M by $3.9M. EPS missed the consensus estimate of $-1.15 by $0.22.
How did CRISPR Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 97.5% from $35.0M a year earlier and eps declined 211.4% from $-0.44.
Where can I find CRISPR Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-048873) and the 10-K periodic report (0001193125-26-048957) directly on SEC EDGAR. The filing index links above go to sec.gov.